TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

AlphaTON’s Cyncado Therapeutics and Australia’s ADDRI to Launch Investigator-Initiated Mesothelioma Clinical Trial of TT-4, Complementing U.S. Plans

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Alphaton Capital Corp
AlphaTON’s Cyncado Therapeutics and Australia’s ADDRI to Launch Investigator-Initiated Mesothelioma Clinical Trial of TT-4, Complementing U.S. Plans

Cyncado Therapeutics and ADDRI are launching an investigator-initiated clinical trial for TT-4, a potential mesothelioma treatment, with planned enrollment of 50 patients in Australia to address the lack of second-line therapy options.

Insights
KVUE   positive

Soared 16% following Kimberly-Clark's $48.7 billion takeover announcement


ATON   neutral

Supporting subsidiary's clinical development efforts while maintaining diverse business interests